Back to Journals » Clinical Interventions in Aging » Volume 1 » Issue 4

Tadalafil in the treatment of erectile dysfunction; an overview of the clinical evidence

Authors Giovanni Vanni Frajese, Flavio Pozzi, Gaetano Frajese

Published 15 January 2007 Volume 2006:1(4) Pages 439—449

Giovanni Vanni Frajese, Flavio Pozzi, Gaetano Frajese

Department of Internal Medicine, Chair of Endocrinology - University of Rome Tor Vergata, Rome, Italy

Abstract: Prevalence and severity of erectile dysfunction (ED) increase with aging and are often associated with illnesses, like diabetes mellitus, heart disease, and hypertension, pathologically characterized by endothelial dysfunction and whose prevalence increases with age. The assumption that ED is mainly a neurovascular disease is supported by the evidence that specific phosphodiesterase type 5 (PDE5) inhibition produces an efficient erection in a wide range of ages and conditions. The availability of specific PDE5 inhibitors has enabled the development of effective treatment strategies, in this contest, tadalafil may be considered as the least “typical” PDE5 inhibitor. In clinical trials, tadalafil significantly enhanced, in patients of different ages, all efficacy outcomes across disease etiologies and severities. With an effectiveness lasting up to 36h, tadalafil allows patients to choose when to have sexual activities without the need to time it, showing positive feedback in terms of quality of life related to the treatment. Headache and dyspepsia were the most frequent side-effects of tadalafil, followed by back pain, nasal congestion, myalgia, and flushing, but the impact that long time action could have on effectiveness and safety is not yet entirely defined. The aim of this article is to critically review the available evidence from the tadalafil clinical research program and give the physician a rational approach for intervention in the treatment of ED and related diseases.

Keywords: tadalafil, PDE5 inhibitors, erectile dysfunction, aging, sexual behavior

Download Article [PDF] 

Readers of this article also read:

The occurrence of cerebrovascular atherosclerosis in Alzheimer’s disease patients

Yuan J, Wen G, Li Y, Liu C

Clinical Interventions in Aging 2013, 8:581-584

Published Date: 24 May 2013

Transdermal hormone therapy and bone health

Lee P Shulman

Clinical Interventions in Aging 2008, 3:51-54

Published Date: 7 March 2008

Walker use, but not falls, is associated with lower physical functioning and health of residents in an assisted-living environment

Daniel A Andersen, Bernard A Roos, Damian C Stanziano, Natasha M Gonzalez, Joseph F Signorile

Clinical Interventions in Aging 2007, 2:123-137

Published Date: 15 April 2007

Utility of tolcapone in fluctuating Parkinson's disease

Fabrizio Stocchi, Maria Francesca De Pandis

Clinical Interventions in Aging 2006, 1:317-325

Published Date: 15 January 2007